27/01/2026
๐๐๐๐ ๐๐๐/๐๐๐ ๐ ๐ฎ๐ข๐๐๐ฅ๐ข๐ง๐๐ฌ ๐จ๐ง ๐๐๐ฎ๐ญ๐ ๐๐ฌ๐๐ก๐๐ฆ๐ข๐ ๐๐ญ๐ซ๐จ๐ค๐ ๐๐ซ๐ ๐จ๐ฎ๐ญ!
1๏ธโฃ ๐๐ข๐ฆ๐ ๐ฌ๐ญ๐ข๐ฅ๐ฅ ๐๐ช๐ฎ๐๐ฅ๐ฌ ๐๐ซ๐๐ข๐ง โ but systems now matter as much as speed
The 2026 guideline strongly emphasizes regional stroke systems of care, advocating integrated EMSโhospital networks with measurable quality metrics and rapid transfer pathways, rather than isolated hospital-centric care .
2๏ธโฃ ๐๐จ๐๐ข๐ฅ๐ ๐๐ญ๐ซ๐จ๐ค๐ ๐๐ง๐ข๐ญ๐ฌ (๐๐๐๐ฌ) ๐๐ซ๐ ๐ง๐จ ๐ฅ๐จ๐ง๐ ๐๐ซ ๐๐ฑ๐ฉ๐๐ซ๐ข๐ฆ๐๐ง๐ญ๐๐ฅ โ they are recommended
Where available, MSUs are recommended over conventional EMS to enable ultra-early thrombolysis and improved functional outcomes, marking a major systems-level upgrade in stroke care .
3๏ธโฃ ๐๐๐ฌ๐ญ๐ข๐ง๐๐ญ๐ข๐จ๐ง ๐ฆ๐๐ญ๐ญ๐๐ซ๐ฌ: Not every stroke should go to the nearest hospital
For suspected LVO, transport decisions should consider direct routing to EVT-capable centers, unless robust and rapid interhospital transfer systems exist โ shifting from โnearestโ to โmost appropriateโ hospital logic .
4๏ธโฃ ๐๐๐ง๐๐๐ญ๐๐ฉ๐ฅ๐๐ฌ๐ ๐ฌ๐ญ๐๐ง๐๐ฌ ๐๐ช๐ฎ๐๐ฅ ๐ญ๐จ ๐๐ฅ๐ญ๐๐ฉ๐ฅ๐๐ฌ๐ ๐ข๐ง ๐ญ๐ก๐ ๐.๐-๐ก๐จ๐ฎ๐ซ ๐ฐ๐ข๐ง๐๐จ๐ฐ
The guideline endorses either alteplase or tenecteplase for IV thrombolysis within 4.5 hours, based on multiple trials showing non-inferiority and practical advantages of tenecteplase (bolus dosing, logistics) .
5๏ธโฃ ๐๐ซ๐๐๐ญ ๐๐ข๐ฌ๐๐๐ฅ๐ข๐ง๐ ๐ฌ๐ญ๐ซ๐จ๐ค๐ ๐ฎ๐ซ๐ ๐๐ง๐ญ๐ฅ๐ฒ โ ๐ข๐ซ๐ซ๐๐ฌ๐ฉ๐๐๐ญ๐ข๐ฏ๐ ๐จ๐ ๐๐๐๐๐ ๐ฌ๐๐จ๐ซ๐
Patients with disabling deficits must receive thrombolysis even with low NIHSS, eliminating the misconception that โlow score = no lysisโ .
6๏ธโฃ ๐๐ฑ๐ญ๐๐ง๐๐๐ ๐ญ๐ก๐ซ๐จ๐ฆ๐๐จ๐ฅ๐ฒ๐ฌ๐ข๐ฌ ๐ง๐จ๐ฐ ๐๐ข๐ซ๐ฆ๐ฅ๐ฒ ๐ข๐ฆ๐๐ ๐-๐ ๐ฎ๐ข๐๐๐
IV thrombolysis is reasonable up to 9 hours or wake-up stroke, provided advanced imaging demonstrates salvageable penumbra (DWI-FLAIR or perfusion mismatch) .
7๏ธโฃ ๐๐ฎ๐๐ฅ ๐๐ง๐ญ๐ข๐ฉ๐ฅ๐๐ญ๐๐ฅ๐๐ญ๐ฌ, ๐ง๐จ๐ญ ๐ญ๐ก๐ซ๐จ๐ฆ๐๐จ๐ฅ๐ฒ๐ฌ๐ข๐ฌ, ๐๐จ๐ซ ๐ง๐จ๐ง-๐๐ข๐ฌ๐๐๐ฅ๐ข๐ง๐ ๐ฆ๐ข๐ง๐จ๐ซ ๐ฌ๐ญ๐ซ๐จ๐ค๐
For minor non-disabling stroke within 4.5 hours, trials failed to show thrombolysis benefit โ DAPT is preferred in this population .
8๏ธโฃ ๐๐๐ ๐ง๐จ๐ฐ ๐๐๐ง๐๐๐ข๐ญ๐ฌ ๐๐ฏ๐๐ง โ๐ฅ๐๐ซ๐ ๐-๐๐จ๐ซ๐โ ๐ฌ๐ญ๐ซ๐จ๐ค๐๐ฌ โ ๐ฌ๐๐ฅ๐๐๐ญ๐๐ ๐ฉ๐๐ญ๐ข๐๐ง๐ญ๐ฌ ๐จ๐ง๐ฅ๐ฒ
The 2026 guideline expands EVT eligibility to some patients with larger ischemic cores, provided imaging and clinical criteria are met โ a paradigm shift from previous exclusions .
9๏ธโฃ ๐๐๐ฌ๐ข๐ฅ๐๐ซ ๐๐ซ๐ญ๐๐ซ๐ฒ ๐จ๐๐๐ฅ๐ฎ๐ฌ๐ข๐จ๐ง: ๐๐๐ ๐ซ๐๐๐จ๐ฆ๐ฆ๐๐ง๐๐๐ ๐ฎ๐ฉ ๐ญ๐จ ๐๐ ๐ก๐จ๐ฎ๐ซ๐ฌ
For basilar artery occlusion with NIHSS โฅ10 and PC-ASPECTS โฅ6, EVT is now strongly recommended within 24 hours โ a major advance in posterior circulation stroke care .
๐ ๐๐๐๐ข๐๐ญ๐ซ๐ข๐ ๐ฌ๐ญ๐ซ๐จ๐ค๐ ๐๐ง๐ญ๐๐ซ๐ฌ ๐ข๐ง๐ญ๐๐ซ๐ฏ๐๐ง๐ญ๐ข๐จ๐ง๐๐ฅ ๐๐ซ๐
For the first time, pediatric AIS is addressed:
EVT is reasonable in select children โฅ6 years (and even younger in expert centers), and alteplase may be considered within 4.5 hours, though efficacy remains uncertain .
1๏ธโฃ1๏ธโฃ ๐๐ง๐ญ๐๐ง๐ฌ๐ข๐ฏ๐ ๐ ๐ฅ๐ฎ๐๐จ๐ฌ๐ ๐ฅ๐จ๐ฐ๐๐ซ๐ข๐ง๐ ๐ข๐ฌ ๐ก๐๐ซ๐ฆ๐๐ฎ๐ฅ โ ๐ง๐จ๐ญ ๐ก๐๐ฅ๐ฉ๐๐ฎ๐ฅ
Targeting glucose aggressively to 80โ130 mg/dL increases hypoglycemia without improving outcomes. Avoid โtightโ glucose control in AIS .
1๏ธโฃ2๏ธโฃ ๐๐ ๐ ๐ซ๐๐ฌ๐ฌ๐ข๐ฏ๐ ๐๐ ๐ฅ๐จ๐ฐ๐๐ซ๐ข๐ง๐ ๐๐๐ญ๐๐ซ ๐ซ๐๐ฉ๐๐ซ๐๐ฎ๐ฌ๐ข๐จ๐ง ๐ฆ๐๐ฒ ๐ฐ๐จ๐ซ๐ฌ๐๐ง ๐จ๐ฎ๐ญ๐๐จ๐ฆ๐๐ฌ
Intensive SBP reduction to